

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**HST Olipudase alfa for treating acid sphingomyelinase  
deficiency (Niemann-Pick disease type B and AB)**

The impact on equality has been assessed during this evaluation according to the principles of the NICE equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

It was noted in the draft scope for consultation that acid sphingomyelinase deficiency is more common in the Ashkenazi Jewish population. However, it was highlighted by clinical experts at the scoping workshop that due to genetic testing in this population, the prevalence of acid sphingomyelinase is no longer different to the general population in this group.
---

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

No equality issues have been identified which need further consideration.
---

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No (although reference to the increased incidence in the Ashkenazi Jewish population has been removed from the final scope).
--

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

**Approved by Associate Director (name):** .....R Diaz.....

**Date:** 14/06/22